by David Wallace For years, the medical community has told us the same thing when we’re diagnosed with early-stage myeloproliferative neoplasms: “Let’s watch and wait.” The thinking was straightforward: why expose someone to treatment side effects when they’re not yet symptomatic? But a study published this December in the journal Cancers is challenging that entire […]